Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ethinyl estradiol + ethynodiol diacetate** is a combination oral contraceptive containing two hormones: ethinyl estradiol (a synthetic estrogen) and ethynodiol diacetate (a synthetic progestin)[1][5][6]. It is used primarily for the **prevention of pregnancy** in women who choose oral contraceptives[1][2][6]. This combination prevents ovulation by suppressing the secretion of gonadotropins (FSH and LH); additionally, it alters cervical mucus to hinder sperm passage and changes the endometrial lining to reduce the likelihood of implantation[1][5][6]. It is formulated as monophasic oral tablets, usually with 21 hormone-containing and 7 inert tablets per cycle[5][8]. No contraceptive method is 100% effective and this medication does not protect against STIs[6]. Rarely, it may be used for management of hormonally related conditions (e.g., acne) when contraception is also desired[7]. The drug contains active ingredients known by their chemical names: ethinyl estradiol (19-nor-17\u03b1-pregna-1,3,5(10)-trien-20-yne-3,17-diol) and ethynodiol diacetate (19-nor-17\u03b1-pregn-4-en-20-yne-3\u03b2,17-diol diacetate)[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinyl estradiol + ethynodiol diacetate.